United Therapeutics (FRA:UTH) Current Accrued Expense : €268 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Current Accrued Expense?

United Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was €268 Mil.

United Therapeutics's quarterly Current Accrued Expense increased from Jun. 2023 (€270 Mil) to Sep. 2023 (€312 Mil) but then declined from Sep. 2023 (€312 Mil) to Dec. 2023 (€268 Mil).

United Therapeutics's annual Current Accrued Expense increased from Dec. 2021 (€151 Mil) to Dec. 2022 (€213 Mil) and increased from Dec. 2022 (€213 Mil) to Dec. 2023 (€268 Mil).

United Therapeutics Current Accrued Expense Historical Data

The historical data trend for United Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Current Accrued Expense Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

124.65

150.34

151.16

213.16

268.13

United Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															213.16	223.88	269.52	312.40	268.13

United Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

United Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (FRA:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (FRA:UTH) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (FRA:UTH) Headlines

No Headlines